Clinical trials: Pulmonary Hypertension, Primary
Hypertension, Pulmonary
A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
GSK2586881, a purified intravenous (IV) formulation of soluble recombinant human Angiotensin Converting Enzyme (rhACE2) is being investigated as a treatment for PAH.
- Trial name
- NCT03177603
- Testing
- GSK2586881
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
PIMR and Pulmonary Vascular Disease
The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH.
- Trial name
- NCT05843461
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Idiopathic Pulmonary Arterial Hypertension
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs.
- Trial name
- NCT00372346
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Pulmonary Arterial Hypertension
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
- Trial name
- NCT05938946
- Testing
- L608 Inhalation Solution
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Hypertension, Pulmonary
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
This is a single center, open-label, randomized, single-dose, three-period cross-over study in healthy participants. The aim of this study is to provide clinically relevant information on the pharmacokinetic (PK) and safety…
- Trial name
- NCT04095286
- Testing
- AMB new formulation (1 mg), Reference AMB (5 mg)
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD.
- Trial name
- NCT04691154
- Testing
- L606 inhalation suspension
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
This study evaluates the effect of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24-week treatment…
- Trial name
- SPECTRA (NCT03738150)
- Testing
- Sotatercept, SOC
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
In preparation for a future mechanistic study, investigators now propose to test the specific hypothesis that carnitine consumption is not reduced in PAH, that plasma carnitine levels are stable over time in PAH and that…
- Conditions
- Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases
- Trial name
- NCT04908397
- Testing
- L-carnitine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension
The primary aim is to evaluate pulmonary function, respiratory muscle strength, upper and lower extremity exercise capacity, muscle oxygenation, dyspnea, peripheral muscle strength, arterial stiffness, physical activity level and…
- Trial name
- NCT06454838
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gazi University
Pulmonary Hypertension Outcome Assessment
Zürich Pulmonary Hypertension Outcome Assessment Cohort
PH is a serious disease with a dismal prognosis and impaired quality of life when left untreated. Reliable patient centered and prognostically relevant outcome measures are highly warranted in the field of PH.
- Trial name
- ZHPHCohort (NCT02249806)
- Testing
- PH target therapy according to physician
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study in two ascending dose cohorts of healthy subjects.
- Trial name
- NCT05660863
- Testing
- MN-08 24 mg/day, MN-08 60 mg/day
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.
Pulmonary Arterial Hypertension
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or…
- Trial name
- NCT05818137
- Testing
- Sotatercept
- Where
- 17 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to see if Lung LLC's new experimental formulation of the medicine Beraprost Sodium, called Beraprost Sodium 314d Modified Release (BPS-314d-MR), can improve the symptoms of pulmonary arterial…
- Trial name
- NCT01966302
- Testing
- BPS-314d-MR
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Pulmonary Hypertension
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
This is a clinical research study designed to evaluate an investigational new medication called sitaxsentan for the treatment of pulmonary arterial hypertension (patients with NYHA functional class II, III or IV).
- Trial name
- NCT00034307
- Testing
- sitaxsentan sodium
- Where
- 26 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- ICOS-Texas Biotechnology
Pulmonary Arterial Hypertension, Dilated Cardiomyopathy
IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy
IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension, Dilated Cardiomyopathy, Congenital Heart Disease
- Trial name
- HEARTFUL-CHD (NCT06072937)
- Testing
- IntelliStent
- Volunteers
- 10 people
- Sponsor
- HeartPoint Global
Pulmonary Arterial Hypertension
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.
- Trial name
- NCT05427162
- Testing
- Prostacyclin Receptor Agonist
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Exercise Training in Patients With Pulmonary Arterial Hypertension
In this study, the effects of kettlebell exercise training on functional capacity, dyspnea and activities of daily living in patients diagnosed with Pulmonary Arterial Hypertension (PAH) will be investigated.
- Trial name
- NCT05242380
- Testing
- Kettlebell Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Saglik Bilimleri Universitesi
Pulmonary Arterial Hypertension (PAH), Sleep-disordered Breathing (SDB)
PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality.
- Trial name
- PAH-SDB (NCT07852403)
- Testing
- Standardized Overnight Sleep and Cardiorespiratory Monitoring
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Hypertension, Bronchopulmonary Dysplasia
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
OBJECTIVES: I. Describe the psychosocial response of parents and caretakers who learn cardiopulmonary resuscitation (CPR) techniques for infants at high risk for respiratory or cardiac arrest. II.
- Conditions
- Pulmonary Hypertension, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
- Trial name
- NCT00004805
- Testing
- CPR instruction
- Volunteers
- 500 people
- Sponsor
- National Center for Research Resources (NCRR)
Pulmonary Arterial Hypertension
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50…
- Trial name
- HEMA-HTP (NCT02800941)
- Testing
- Oral anticoagulant treatment
- Where
- 4 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne